ZIMMER BIOMET HOLDINGS, INC.
No SEC Form 4 filings for $ZBH in the last 30 days.
Zimmer Biomet reported Q2 2026 organic constant-currency revenue growth of 4%, led by a 4.6% U.S. increase and 3.1% international growth. Management raised full-year organic guidance to 2.25%-3.25% and adjusted EPS to $8.47-$8.59, including $1B planned 2026 share repurchases. China revenue fell 20%.
Zimmer Biomet (NYSE:ZBH) reported Q2 adjusted EPS of $2.07, above the $2.01 consensus, and revenue of $2.18B, up 4.8% year over year and above the $2.14B estimate. The company raised FY2026 guidance to $8.47-$8.59 adjusted EPS and 3.9%-4.9% reported sales growth, and expects up to $1B in share repurchases.
Bernstein raised its price target on Zimmer Biomet to $93 from $91, according to the report. The article also notes a separate Jefferies price target change to $105 from $95. Investors may use these analyst updates as inputs for valuation and expectations for the stock.
Over the past 7 days, alphai's AI scored 12 news stories mentioning ZBH (ZIMMER BIOMET HOLDINGS, INC.). Coverage has skewed bullish: 10 bullish, 2 neutral, and 0 bearish.
Recent ZBH coverage spans earnings and financial news.
Guidance and capital return upgrades, alongside margin pressure from front-loaded U.S. investments, set up a near-term earnings revision and positioning catalyst.
Raised full-year guidance plus a $1B buyback expectation supports near-term upside bias, but execution risk remains if demand or margins soften.
A sell-side price-target change can move sentiment and near-term positioning, but the article provides no new fundamentals beyond the target revision.
Guidance raise plus Q2 revenue beat supports near-term upside bias, but traders will watch whether segment mix and margins sustain.
Guidance lift and EPS range expansion suggest improved earnings visibility, supporting near-term upside bias versus prior expectations.
alphai scores every news story that mentions ZBH with an AI model for sentiment and relevance, and aggregates insider trades from ZIMMER BIOMET HOLDINGS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Zimmer Biomet reported Q2 2026 organic constant-currency revenue growth of 4%, led by a 4.6% U.S. increase and 3.1% international growth. Management raised full-year organic guidance to 2.25%-3.25% and adjusted EPS to $8.47-$8.59, including $1B planned 2026 share repurchases. China revenue fell 20%.
7 min readZimmer Biomet (NYSE:ZBH) reported Q2 adjusted EPS of $2.07, above the $2.01 consensus, and revenue of $2.18B, up 4.8% year over year and above the $2.14B estimate. The company raised FY2026 guidance to $8.47-$8.59 adjusted EPS and 3.9%-4.9% reported sales growth, and expects up to $1B in share repurchases.
3 min readBernstein raised its price target on Zimmer Biomet to $93 from $91, according to the report. The article also notes a separate Jefferies price target change to $105 from $95. Investors may use these analyst updates as inputs for valuation and expectations for the stock.
1 min readZimmer Biomet reported Q2 revenue of about $2.18bn, up 4.8% YoY. Knees led at $828.9m, followed by S.E.T. at $586m and hips at $562.7m. The company raised its 2026 revenue growth outlook to 3.9% to 4.9% and adjusted EPS to $8.47 to $8.59 per diluted share. Shares rose over 5% to about $101 at the open.
4 min readZimmer Biomet (ZBH) reported Q2 net earnings of $198.3 million, or $1.03 per share, versus $152.8 million, or $0.77 per share, a year earlier. Net sales rose to $2,177.0 million from $2,077.3 million. For FY2026, it raised reported revenue growth to 3.9% to 4.9% and adjusted EPS to $8.47 to $8.59. Shares were up pre-market to $100.15.
2 min readZimmer Biomet (ZBH) reported Q2 2026 adjusted EPS of $2.07, above the $2.01 consensus, and net sales of $2.18B, above the $2.13B estimate. GAAP EPS was $1.03. The company raised 2026 guidance, including revenue growth to 3.9% to 4.9% and adjusted EPS to $8.47 to $8.59. Shares rose 1.4% pre-market.
7 min readZimmer Biomet (ZBH) reported Q2 2026 net sales of $2.177B (+4.8%) and GAAP diluted EPS of $1.03 (+33.8%), with technology sales up 53% in the U.S. Hip sales grew about 6% and knees were nearly flat. The company raised 2026 organic revenue growth to 2.25%–3.25% and adjusted EPS to $8.47–$8.59, and plans up to $1B buybacks.
7 min readZimmer Biomet (ZBH) reported Q2 sales up 4.8% reported and 4% organically, citing strength in the U.S. and technology segments. The company said product momentum and the Paragon 28 integration supported results and raised 2026 guidance for both revenue and adjusted EPS, according to its Q2 2026 transcript.
1 min readZimmer Biomet (NYSE:ZBH) reported Q2 CY2026 revenue of $2.18 billion, up 4.8% year on year and 2% above analysts’ estimates, according to the company. Non-GAAP adjusted EPS was $2.07, about 3% above consensus. The article also cites full-year EPS expectations rising from $8.48 to $8.72 and notes the stock rose about 3% to $98.68 after results.
4 min readZimmer Biomet (ZBH) shares rose about 4.5% in pre-open after the company reported Q2 2026 results. Analysts expected EPS of $2.01 and revenue of about $2.13–$2.14B; the company beat estimates. UBS upgraded ZBH to Buy from Sell on July 28, setting a $115 target. Peer results from CONMED and Baxter also beat.
3 min read
